Summary

CETP rs5882 and rs2542052 determine how actively your blood redistributes cholesterol from HDL to LDL — reduced CETP activity (Val allele at rs5882, A allele at rs2542052) raises HDL levels naturally and has been associated with cardiovascular protection and longevity, though the clinical picture is more nuanced than "higher HDL = better."

Genotype spectrum

GG (Ile/Ile — Common)

Your CETP-mediated cholesterol transfer is at full activity. Your HDL-C levels are determined by other genetic and lifestyle factors — CETP is not giving you a boost or disadvantage here.

AG (Ile/Val — Heterozygous)

You have a natural lipid advantage. Your moderately reduced CETP preserves more cholesterol in HDL particles.

AA (Val/Val — Homozygous Val)

You have the most favourable CETP genotype for lipid profile. Your naturally higher HDL and lower LDL represent a genuine cardiovascular advantage that has been associated with longevity in centenarian studies.

Practical takeaway

For GG Carriers (Ile/Ile — Standard CETP)

Standard cardiovascular health:
• Regular aerobic exercise is the most reliable lifestyle intervention for raising HDL-C and improving HDL functionality.
• Healthy weight maintenance. Obesity lowers HDL-C.
• Dietary quality: Mediterranean pattern, adequate omega-3, moderate alcohol if consumed.
• Standard lipid panel monitoring: every 5 years from age 20, annually from 40 (or earlier if family history).
For AG Carriers (Ile/Val — Modestly Reduced CETP)

Your lipid advantage in context:
• Your slightly higher HDL-C is genetic. When interpreting lipid panels, note that your HDL baseline is naturally elevated.
• This is a positive finding — lean into it with exercise and dietary quality.
• Don't become complacent. HDL-C is one of many cardiovascular risk factors. Blood pressure, LDL-C, triglycerides, inflammation, and metabolic health all matter independently.
For AA Carriers (Val/Val — Substantially Reduced CETP)

Positive finding — capitalise on it:
• Your HDL-C is naturally elevated, potentially 10-15% above population average. This is a genuine cardiovascular advantage.
• When discussing lipid panels with your doctor, mention CETP genotype. Your "high" HDL is partly genetic, which is important context for risk assessment.
• Exercise amplifies your advantage. Regular aerobic activity further raises HDL-C and improves particle functionality.
• This is one of the few variants with a direct longevity association — the centenarian studies are genuine positive evidence.

What to monitor: Standard lipid panels. Note your HDL-C trend over time rather than comparing to population reference ranges (your range is genetically shifted upward).

Expected response window: Lipid effects of exercise are measurable within 4-8 weeks. Cardiovascular risk modification from sustained HDL advantage accrues over years and decades.

Evidence detail

What This Gene Does

CETP encodes cholesteryl ester transfer protein, a plasma glycoprotein secreted primarily by the liver. CETP's function is to facilitate the transfer of cholesteryl esters from HDL particles to LDL and VLDL particles in exchange for triglycerides. This process is part of reverse cholesterol transport — the pathway that moves cholesterol from peripheral tissues back to the liver for excretion.

CETP effectively "redistributes" cholesterol between lipoprotein classes. High CETP activity transfers cholesterol from HDL → LDL/VLDL, reducing HDL-C levels and increasing LDL-C levels. Low CETP activity preserves cholesterol in HDL particles, resulting in higher HDL-C and lower LDL-C. The question of whether this HDL preservation is genuinely cardioprotective has been one of the most debated topics in cardiovascular genetics and pharmacology.

The rs5882 variant (Ile405Val) changes a residue that affects CETP secretion and activity. The Val (A) allele reduces CETP activity, resulting in higher HDL-C levels. The rs2542052 variant sits in the CETP promoter region — the A allele reduces CETP transcription, further lowering CETP protein levels.

Mechanism

Reverse cholesterol transport — the HDL highway:

The cardiovascular system maintains cholesterol balance through reverse cholesterol transport (RCT):

1. Cholesterol efflux: Peripheral cells (including macrophages in artery walls) export excess cholesterol to nascent HDL particles via ABCA1 and ABCG1 transporters.
2. HDL maturation: Free cholesterol on HDL is esterified by LCAT (lecithin-cholesterol acyltransferase), converting disc-shaped nascent HDL into spherical, cholesteryl ester-rich mature HDL.
3. CETP transfer: CETP transfers cholesteryl esters from mature HDL to LDL/VLDL in exchange for triglycerides. This depletes HDL of cholesterol (lowering HDL-C) and enriches LDL (raising LDL-C).
4. Hepatic clearance: Cholesterol reaches the liver either directly (HDL via SR-BI receptor) or indirectly (LDL via LDL receptor after CETP-mediated transfer).

What reduced CETP activity does:

When CETP activity is low (Val allele carriers):
• Less cholesterol transfers from HDL → LDL: HDL-C stays high, LDL-C stays low
• HDL particles are larger and more cholesterol-rich
• The direct RCT pathway (HDL → liver via SR-BI) predominates
• Net effect: higher HDL-C, lower LDL-C, larger HDL particle size

The HDL quantity vs functionality debate:

The CETP inhibitor trials taught a critical lesson: HDL-C concentration (what blood tests measure) is not the same as HDL functionality (what actually protects arteries). Genetically higher HDL (from CETP variants) comes with larger, more functional particles that have had more time to accumulate cholesterol via efflux. Pharmacologically raised HDL may produce particles with different properties.

The Mendelian randomisation data (Voight 2012) suggests that HDL-C per se may not be causally protective — rather, the constellation of metabolic changes associated with low CETP activity (higher HDL, lower LDL, better particle profiles) collectively reduce risk. This is why genetically low CETP activity is associated with cardiovascular benefit even though pharmaceutical HDL-raising has had mixed results.

CETP Hdl

Summary

Genotype spectrum

Practical takeaway

Evidence detail

Sources (8)